BR112022001080A2 - Materiais e métodos para direcionamento do receptor de anticorpo polimérico - Google Patents
Materiais e métodos para direcionamento do receptor de anticorpo poliméricoInfo
- Publication number
- BR112022001080A2 BR112022001080A2 BR112022001080A BR112022001080A BR112022001080A2 BR 112022001080 A2 BR112022001080 A2 BR 112022001080A2 BR 112022001080 A BR112022001080 A BR 112022001080A BR 112022001080 A BR112022001080 A BR 112022001080A BR 112022001080 A2 BR112022001080 A2 BR 112022001080A2
- Authority
- BR
- Brazil
- Prior art keywords
- pigr
- targeting
- materials
- methods
- antibody receptor
- Prior art date
Links
- 239000000463 material Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 101150095279 PIGR gene Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 150000002605 large molecules Chemical class 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 230000031998 transcytosis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
MATERIAIS E MÉTODOS PARA DIRECIONAMENTO DO RECEPTOR DE ANTICORPO POLIMÉRICO. A presente invenção refere-se a domínios VHH que se ligam ao pIgR. O domínio VHH pode competir com a ligação de IgA ao pIgR, ou alternativamente, o domínio VHH pode competir com a ligação de IgA ao pIgR. Os domínios VHH podem ser acoplados a agentes terapêuticos, de modo a facilitar a liberação do agente terapêutico à camada de mucosa por transcitose mediada por pIgR. O agente terapêutico pode ser uma molécula pequena, uma molécula grande ou mesmo um anticorpo.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882387P | 2019-08-02 | 2019-08-02 | |
US201962882346P | 2019-08-02 | 2019-08-02 | |
US201962882291P | 2019-08-02 | 2019-08-02 | |
US201962882361P | 2019-08-02 | 2019-08-02 | |
US201962940208P | 2019-11-25 | 2019-11-25 | |
US201962940196P | 2019-11-25 | 2019-11-25 | |
US201962940206P | 2019-11-25 | 2019-11-25 | |
US201962940228P | 2019-11-25 | 2019-11-25 | |
US201962940220P | 2019-11-25 | 2019-11-25 | |
US201962940200P | 2019-11-25 | 2019-11-25 | |
US201962940232P | 2019-11-25 | 2019-11-25 | |
PCT/US2020/044505 WO2021026000A1 (en) | 2019-08-02 | 2020-07-31 | Materials and methods for polymeric antibody receptor targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001080A2 true BR112022001080A2 (pt) | 2022-07-19 |
Family
ID=74502941
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001352A BR112022001352A2 (pt) | 2019-08-02 | 2020-07-31 | Materiais e métodos para biotransporte multidirecional |
BR112022001080A BR112022001080A2 (pt) | 2019-08-02 | 2020-07-31 | Materiais e métodos para direcionamento do receptor de anticorpo polimérico |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001352A BR112022001352A2 (pt) | 2019-08-02 | 2020-07-31 | Materiais e métodos para biotransporte multidirecional |
Country Status (18)
Country | Link |
---|---|
US (2) | US20230019640A1 (pt) |
EP (2) | EP4007607A4 (pt) |
JP (2) | JP2022542391A (pt) |
KR (2) | KR20220054585A (pt) |
CN (2) | CN114173801A (pt) |
AU (2) | AU2020326589A1 (pt) |
BR (2) | BR112022001352A2 (pt) |
CA (2) | CA3147916A1 (pt) |
CO (2) | CO2022000817A2 (pt) |
CR (2) | CR20220042A (pt) |
DO (2) | DOP2022000022A (pt) |
EC (2) | ECSP22007690A (pt) |
IL (2) | IL289955A (pt) |
JO (1) | JOP20220025A1 (pt) |
MX (2) | MX2022001278A (pt) |
PE (2) | PE20220298A1 (pt) |
TW (2) | TW202122108A (pt) |
WO (2) | WO2021026000A1 (pt) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU728587B2 (en) * | 1996-06-04 | 2001-01-11 | Regents Of The University Of California, The | Cellular internalization of pIgR stalk and associated ligands |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
WO2000047611A2 (en) * | 1999-02-12 | 2000-08-17 | Oklahoma Medical Research Foundation | Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor |
EP1268555A2 (en) * | 2000-03-27 | 2003-01-02 | The Regents of The University of California | Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
MXPA03002918A (es) * | 2000-10-02 | 2004-04-20 | Arizeke Pharmaceuticals Inc | Composiciones y metodos para el transporte de agentes biologicamente activos a traves de barreras celulares. |
US20030166160A1 (en) * | 2001-09-06 | 2003-09-04 | Hawley Stephen B. | Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands |
AU2002305140A1 (en) * | 2001-04-03 | 2002-10-28 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions |
AU2004204763A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
EP2753644A1 (en) * | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
AU2013201422B2 (en) * | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
EP2917731B1 (en) * | 2012-11-08 | 2019-12-25 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Diagnostic, prognostic, therapeutic and screening protocols |
WO2017172517A1 (en) * | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
WO2018222506A1 (en) * | 2017-05-27 | 2018-12-06 | Immune-Onc Therapeutics, Inc. | Modulation of immunoglobulin-a-positive cells |
-
2020
- 2020-07-31 EP EP20850058.7A patent/EP4007607A4/en active Pending
- 2020-07-31 MX MX2022001278A patent/MX2022001278A/es unknown
- 2020-07-31 TW TW109126108A patent/TW202122108A/zh unknown
- 2020-07-31 BR BR112022001352A patent/BR112022001352A2/pt not_active Application Discontinuation
- 2020-07-31 JO JOP/2022/0025A patent/JOP20220025A1/ar unknown
- 2020-07-31 CR CR20220042A patent/CR20220042A/es unknown
- 2020-07-31 PE PE2022000180A patent/PE20220298A1/es unknown
- 2020-07-31 CA CA3147916A patent/CA3147916A1/en not_active Abandoned
- 2020-07-31 AU AU2020326589A patent/AU2020326589A1/en active Pending
- 2020-07-31 JP JP2022506123A patent/JP2022542391A/ja active Pending
- 2020-07-31 WO PCT/US2020/044505 patent/WO2021026000A1/en active Application Filing
- 2020-07-31 KR KR1020227003638A patent/KR20220054585A/ko unknown
- 2020-07-31 CN CN202080055485.8A patent/CN114173801A/zh active Pending
- 2020-07-31 TW TW109126094A patent/TW202116813A/zh unknown
- 2020-07-31 PE PE2022000168A patent/PE20220344A1/es unknown
- 2020-07-31 CR CR20220043A patent/CR20220043A/es unknown
- 2020-07-31 CN CN202080061126.3A patent/CN114423451A/zh active Pending
- 2020-07-31 KR KR1020227003585A patent/KR20220054289A/ko unknown
- 2020-07-31 WO PCT/US2020/044497 patent/WO2021025997A1/en active Application Filing
- 2020-07-31 CA CA3147905A patent/CA3147905A1/en not_active Abandoned
- 2020-07-31 US US17/630,706 patent/US20230019640A1/en active Pending
- 2020-07-31 BR BR112022001080A patent/BR112022001080A2/pt not_active Application Discontinuation
- 2020-07-31 US US17/630,718 patent/US20220324970A1/en active Pending
- 2020-07-31 JP JP2022506274A patent/JP2022542418A/ja active Pending
- 2020-07-31 EP EP20849929.3A patent/EP4007591A4/en active Pending
- 2020-07-31 MX MX2022001379A patent/MX2022001379A/es unknown
- 2020-07-31 AU AU2020326590A patent/AU2020326590A1/en active Pending
-
2022
- 2022-01-18 IL IL289955A patent/IL289955A/en unknown
- 2022-01-18 IL IL289956A patent/IL289956A/en unknown
- 2022-01-28 DO DO2022000022A patent/DOP2022000022A/es unknown
- 2022-01-28 DO DO2022000021A patent/DOP2022000021A/es unknown
- 2022-01-28 CO CONC2022/0000817A patent/CO2022000817A2/es unknown
- 2022-01-31 EC ECSENADI20227690A patent/ECSP22007690A/es unknown
- 2022-02-16 CO CONC2022/0001579A patent/CO2022001579A2/es unknown
- 2022-02-24 EC ECSENADI202214913A patent/ECSP22014913A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001452A1 (es) | Composiciones anti-cgrp y uso de las mismas (divisional solicitud 201701379) | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
BR112019008417A2 (pt) | compostos de peptídeo tirosina-tirosina cíclico acoplados a anticorpo como moduladores de receptores de neuropeptídeo y | |
CL2013001468A1 (es) | Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre. | |
MA34287B1 (fr) | Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6) | |
WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
WO2020082209A8 (zh) | 抗cldn18.2抗体及其用途 | |
BR112016020643A2 (pt) | anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos | |
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
UA117570C2 (uk) | Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті | |
BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
NO20080302L (no) | Humane anti-B7RP1 noytraliserende antistoffer | |
EA201100239A1 (ru) | Композиции, одновалетные в отношении связывания cd28, и способы их применения | |
BR112018007318A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição. | |
BRPI0906478B8 (pt) | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende | |
BR112012016992A2 (pt) | "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena". | |
BR112022005423A2 (pt) | Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap) | |
BR112017007877A2 (pt) | anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado | |
BR112022003628A2 (pt) | Conjugados de dendrímero direcionado | |
BR112017018678A2 (pt) | anticorpos de igg modificada que ligam o fator de crescimento de transformação beta1 com afinidade, avidez e especificidade altas | |
BR112016014163A2 (pt) | anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado | |
PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |